Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 3:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,233 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Nab paclitaxel, Gemcitabine, TheraBionic P1
Drug · Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Clarkston, Michigan • Detroit, Michigan • Flint, Michigan + 4 more
Conditions
Metastatic Pancreatic Cancer
Interventions
Gemcitabine, Nab-paclitaxel, Aldoxorubicin HCl, ALT-803, ETBX-011, ETBX-021, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK, Avelumab, Bevacizumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, Oxaliplatin
Drug · Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
El Segundo, California
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Nodal Marginal Zone Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cytarabine, Dexamethasone, Epcoritamab, Etoposide Phosphate, Gemcitabine, Ifosfamide, Multigated Acquisition Scan, Oxaliplatin, Rituximab
Procedure · Drug · Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Results available

The HOPE Trial and the SMART Study

NCT03022032
Conditions
Gynecologic Cancer
Interventions
Fitbit Zip, HOPE App, Standard of Care, Fitbit Charge 2, SMART Study Intervention
Device · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions
MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin, MK-3475 (adjuvant), Peripheral blood
Biological · Procedure · Radiation + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York
Conditions
Child, Only, Disabilities Multiple, Medication Interaction, Medication Compliance, Medication Administered in Error
Interventions
Pediatric Medication Therapy Management (pMTM)
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 18 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Any Solid Oral Medication
Interventions
Use of ReX to dispense and monitor solid oral medication therapy.
Device
Lead sponsor
Dosentrx Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Non Small Cell Lung Cancer, NSCLC, Stage III, Nsclc
Interventions
Durvalumab, Carboplatin, Pemetrexed, Paclitaxel, Cisplatin, AVENIO ctDNA Surveillance Kit, Tremelimumab
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Conditions
Diarrhea, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer
Interventions
Laboratory Biomarker Analysis, Micronutrient-Fortified Probiotic Yogurt, VEGF-TKI
Other · Dietary Supplement · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Duarte, California
Conditions
Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions
melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
Drug · Procedure
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
Conditions
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Interventions
Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Colorectal Cancer Stage II, Colorectal Cancer Stage III
Interventions
Regular blood sample collection for ctDNA assessment
Procedure
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
2,079 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
17
States / cities
California City, California • Concord, California • Greenbrae, California + 14 more
Conditions
Systemic Lupus Erythematosus
Interventions
Preventive Cardiology, Usual Care
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
19 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Doxycycline, Hydrocortisone 1% cream, Sunscreen, Moisturizer, Clindamycin, Medrol-dose pack (Steroid)
Drug · Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma, Refractory Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Paclitaxel, Sacituzumab Govitecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
448
States / cities
Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 306 more
Conditions
Suicidal Ideation
Interventions
Ketamine Injectable Solution, Placebo Injection, Crisis Response Plan, Safety Planning
Drug · Other · Behavioral
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fort Hood, Texas • San Antonio, Texas
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Diffusion Weighted Imaging
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Radiation Therapy, Pembrolizumab, Nab-paclitaxel, Paclitaxel, Carboplatin, Gemcitabine, Biopsy, Computed Tomography, Bone Scan, Biospecimen Collection, Medical Chart Review
Radiation · Biological · Drug + 2 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Human Papilloma Virus, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, HPV-Related Squamous Cell Carcinoma, HNSCC
Interventions
Carboplatin, Paclitaxel, Nivolumab, Radiation, Hydroxyurea Pill, 5-fluorouracil, Filgrastim Injection, Cisplatin
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Fluorouracil, Irinotecan, Leucovorin, Lymph Node Biopsy, Magnetic Resonance Imaging, Oxaliplatin, Pembrolizumab, Photodynamic Therapy, Positron Emission Tomography, Questionnaire Administration, Verteporfin
Procedure · Drug · Biological + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Conditions
Cervical Cancer, Vaginal Cancer
Interventions
therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Cancer
Interventions
ACTS Intervention, Usual Care
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania